• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Life Sciences | News, Analysis, Insights - HIT Consultant

GSK Launches Accelerated Clinical Trial with Tempus

by Jasmine Pennic 01/13/2022 Leave a Comment

Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative to Advance Precision Cancer Treatment

What You Should Know: - Tempus and GlaxoSmithKline (GSK) announced an accelerated phase II study evaluating the efficacy and safety of niraparib, an oral, once daily PARP inhibitor, for patients with breast and pancreatic cancers. The study, titled “Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors” (the PAVO study, NCT05169437) is sponsored by Tempus and opened for enrollment on January 7, 2022. - This trial’s data-driven design and site selection
Read More

Sanofi Taps BrightInsight for Development of Software as a Medical Device

by Fred Pennic 01/13/2022 Leave a Comment

Sanofi, TriNetX Partner to Optimize Clinical Trials with Digital Technology

What You Should Know: - Sanofi, a global biopharmaceutical company focused on human health has inked a strategic partnership with  BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solution to bring to market a next-generation digital companion application for one of Sanofi’s products. - The BrightInsight® Platform has been selected to serve as the underlying infrastructure to accelerate continuous development of one of Sanofi’s
Read More

PostEra Secures $24M, Forms $260M AI Lab Collaboration with Pfizer

by Fred Pennic 01/11/2022 Leave a Comment

PostEra Secures $24M, Forms $260M AI Lab Collaboration with Pfizer

What You Should Know: - PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients. - PostEra will use the proceeds to advance a series of partnered drug discovery programs, initiate its own internal drug discovery, and further develop its medicinal chemistry platform. True to its collaborative ethos, the company today also announced its
Read More

Verily, Sosei Heptares Collaborate to Generate Novel Drug Candidates Against GPCR Targets for Immune-Mediated Diseases

by Jasmine Pennic 01/06/2022 Leave a Comment

Verily, Sosei Heptares Collaborate to Generate Novel Drug Candidates Against GPCR Targets for Immune-Mediated Diseases

What You Should Know: - Verily and Sosei Heptares announced a new research collaboration combining Verily’s Immune Profiler platform, a next gen immune mapping platform, with Sosei Heptares’ world-leading StaR (stabilized receptor) platform, with the goal of rapidly identifying novel drug candidates across multiple immune-based disorders. - Together, the collaboration will focus on accelerating the development of new drug candidates against
Read More

Protai Nabs $8M for AI-Powered Drug Discovery Platform

by Fred Pennic 01/05/2022 Leave a Comment

Protai Nabs $8M for AI-Powered Drug Discovery Platform

What You Should Know: - Protai, a Tel Aviv, Israel-based AI-powered drug discovery startup, today announced its emergence from stealth, along with an $8 million seed financing round co-led by Grove Ventures and Pitango HealthTech. - Protai empowers drug discovery with proteomics and artificial intelligence to unlock new layers of biological insights and to combat complex diseases. Proteomics-based Platform for Faster and More Accurate Drug Discovery Despite the significant
Read More

Illumina and Syapse Partner on Biomarker Testing Research Across Oncology Practices

by Jasmine Pennic 01/05/2022 Leave a Comment

Illumina and Syapse Partner on Biomarker Testing Research Across Oncology Practices

What You Should Know: - Syapse, a real-world evidence company that informs cancer care, announced a partnership with Illumina aimed at assessing the real-world uptake and actionability of comprehensive genomic profiling in the community oncology health system setting. - Together, the two companies will work to better understand biomarker testing patterns among clinicians, which have become foundational in identifying treatment options for cancer patients. The insights gleaned from this
Read More

COVID-19: As Omicron Variant Spreads, Let’s Not Repeat Rookie Mistakes

by Boaz Roseman, CEO of A.L. GROUP 12/28/2021 Leave a Comment

COVID-19: As Omicron Variant Spreads, Let’s Not Repeat Rookie Mistakes

No one should be surprised there’s another COVID variant on the loose, and yet seemingly, everyone is. The variant, named Omicron (the fifteenth letter in the Greek alphabet), was first reported to the World Health Organisation (WHO) by South Africa on November 24th. Unlike its name would suggest, Omicron is the seventh COVID-19 variant of concern—but a pandemic-fatigued global public could be forgiven for thinking it’s the twentieth.  Governments across the developed world have pushed
Read More

Quidel Corporation Acquires Ortho Clinical Diagnostics for $6B

by Fred Pennic 12/28/2021 Leave a Comment

Quidel Corporation Acquires Ortho Clinical Diagnostics for $6B

What You Should Know: - Quidel Corporation (NASDAQ: QDEL) (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho”) jointly announced that they have entered into a definitive agreement in which Quidel will acquire Ortho. - The acquisition will create a global leader in diagnostics, bringing together two highly complementary portfolios with world-class technologies and platforms spanning high-throughput systems to near-patient and at-home testing. Financial Terms of
Read More

Northwell Launches Virtual Clinical Trial to Reduce Cardiovascular Disease in Black Community

by Fred Pennic 12/21/2021 Leave a Comment

Northwell Launches Virtual Clinical Trial to Reduce Cardiovascular Disease in Black Community

What You Should Know: - The Feinstein Institutes for Medical Research, the science arm of Northwell Health, recently received a $150k grant from TD Bank, America's Most Convenient Bank, to launch a new research program and the first clinical trial to reduce cardiovascular disease in the Black community and determine the best behavioral interventions to lower Cardiovascular disease (CVD). Impact of Cardiovascular Disease in Black Community Cardiovascular disease (CVD) is a major driver
Read More

How 3D Printing is Revolutionizing Orthotics for Patients and Providers

by Philipp Jung, GM of Arize and Global Head of Orthotic Solutions at HP Inc. 12/20/2021 Leave a Comment

How 3D Printing is Revolutionizing Orthotics for Patients and Providers

For the 77% of Americans who suffer from foot pain,1 seeking relief has included a litany of options: medications, exercises, insoles and even surgery to name a few. But relief is often hit-or-miss, and insoles that are customized traditionally include a very time-consuming process for patients. They often require lengthy office visits, multiple fit adjustments and even then, not always offering the right fit.  Fortunately, advancements in technology are changing the game. Software,
Read More

  • Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 61
  • Go to page 62
  • Go to page 63
  • Go to page 64
  • Go to page 65
  • Interim pages omitted …
  • Go to page 86
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Healthcare's Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Healthcare’s Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |